Wall Street analysts expect Evolent Health Inc (NYSE:EVH) to post sales of $189.05 million for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Evolent Health’s earnings, with estimates ranging from $187.67 million to $190.79 million. Evolent Health reported sales of $113.97 million in the same quarter last year, which would suggest a positive year over year growth rate of 65.9%. The business is scheduled to issue its next earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Evolent Health will report full year sales of $627.53 million for the current financial year, with estimates ranging from $621.70 million to $629.89 million. For the next fiscal year, analysts expect that the business will post sales of $859.48 million, with estimates ranging from $837.10 million to $876.92 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Evolent Health.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Tuesday, November 6th. The technology company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $150.16 million during the quarter, compared to analysts’ expectations of $142.94 million. Evolent Health had a negative return on equity of 2.18% and a negative net margin of 9.05%. The company’s revenue was up 38.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.18) EPS.

A number of research firms have recently weighed in on EVH. ValuEngine upgraded Evolent Health from a “buy” rating to a “strong-buy” rating in a report on Friday, September 14th. Canaccord Genuity increased their price target on Evolent Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Thursday, September 13th. Leerink Swann set a $35.00 price target on Evolent Health and gave the stock a “buy” rating in a report on Friday, October 5th. Citigroup increased their target price on Evolent Health from $25.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, October 4th. Finally, KeyCorp reissued an “overweight” rating and set a $32.00 target price (up previously from $28.00) on shares of Evolent Health in a research note on Thursday, September 13th. They noted that the move was a valuation call. Thirteen investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $31.82.

Shares of NYSE EVH traded down $0.19 during mid-day trading on Tuesday, reaching $20.61. 10,066 shares of the company’s stock were exchanged, compared to its average volume of 655,577. The stock has a market cap of $1.82 billion, a PE ratio of -29.13 and a beta of 1.54. The company has a current ratio of 2.50, a quick ratio of 2.50 and a debt-to-equity ratio of 0.12. Evolent Health has a 52-week low of $12.30 and a 52-week high of $29.05.

In other Evolent Health news, General Counsel Jonathan Weinberg sold 15,000 shares of the stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $27.12, for a total value of $406,800.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Thomas Peterson III sold 70,000 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $27.50, for a total value of $1,925,000.00. The disclosure for this sale can be found here. 4.82% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Capital Research Global Investors raised its position in shares of Evolent Health by 3.9% during the 3rd quarter. Capital Research Global Investors now owns 7,642,195 shares of the technology company’s stock worth $217,038,000 after acquiring an additional 288,195 shares in the last quarter. Vanguard Group Inc. grew its stake in Evolent Health by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,713,530 shares of the technology company’s stock worth $162,264,000 after buying an additional 439,172 shares during the last quarter. BlackRock Inc. grew its stake in Evolent Health by 4.8% during the 3rd quarter. BlackRock Inc. now owns 4,571,771 shares of the technology company’s stock worth $129,838,000 after buying an additional 209,540 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Evolent Health by 13.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,187,652 shares of the technology company’s stock worth $90,529,000 after buying an additional 368,932 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its stake in Evolent Health by 29.3% during the 2nd quarter. Eagle Asset Management Inc. now owns 2,574,180 shares of the technology company’s stock worth $54,186,000 after buying an additional 582,666 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Read More: Can individual investors take part in an IPO?

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.